Comprehensive Opioid Management and Breathing During Sleep

ClinicalTrials.gov ID: NCT07923721

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT07923721. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 12, 2026, 9:26 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Respiratory Effects of Dose Optimization Under Comprehensive Opioid Management (REDUCE)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The REDUCE study will evaluate whether referral to a comprehensive opioid management program improves breathing stability during sleep in adults with chronic opioid use and sleep-disordered breathing. This is a Phase II, single-center, randomized, controlled study. Participants will be randomly assigned to either usual care or referral to the UC San Diego Opioid Management Program. Participants referred to the program will receive individualized opioid and pain management from their treating clinician or designated opioid management provider. Treatment may include changes to opioid medications and other pain-management strategies when clinically appropriate. The research team will not prescribe opioids or direct opioid dose adjustments, and no opioid dose reductions are required by the study. Participants will be followed for approximately 26 weeks. Study assessments will include overnight sleep studies, questionnaires, blood collection, psychomotor vigilance testing, and regular safety monitoring. The primary objective is to determine whether comprehensive opioid management improves ventilatory stability compared with usual care.

Study identification

NCT ID: NCT07923721
Recruitment status: Not yet recruiting
Study type: Interventional
Phase: Not applicable
Lead sponsor: University of California, San Diego; Other
Enrollment: 68 participants

Conditions and interventions

Conditions

Interventions

Comprehensive Opioid Management Other
Usual Care Other

Other

Eligibility (public fields only)

Age range: 18 Years to 75 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Dec 1, 2026 (Estimated)
Primary completion: Dec 1, 2031 (Estimated)
Completion: Dec 1, 2031 (Estimated)
Last update posted: Nov 6, 2026

2026 – 2031

United States locations

U.S. sites: 1
U.S. states: 1
U.S. cities: 1

Facility	City	State	ZIP	Site status
Altman Clinical and Translational Research Institute	La Jolla	California	92037	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07923721, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Nov 6, 2026 · Synced Nov 12, 2026